Andere talen Neurogene Inc.

Aandelen

NGNE

US64135M1053

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
29,87 ^USD	-1,19%		-5,41%	+54,13%

21/03	NEUROGENE INC. : William Blair & Co. nog altijd een koopadvies	ZM
18/03	Neurogene Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22/04
North American Morning Briefing : Stocks Struggle After New Records	22/03
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18/03
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
North American Morning Briefing : Inflation -2-	15/03
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene to Participate in Upcoming Investor Conferences	29/02
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	21/02
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	17/01
Neurogene Names Julie Jordan as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01
Neurogene Announces Business Update and 2024 Outlook	05/01
Neurogene Announces Business Update and 2024 Outlook	05/01
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	20/12
Neurogene Completes Merger With Neoleukin Therapeutics	19/12
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K	19/12
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	18/12
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Neurogene Inc.

Aandelen

NGNE

US64135M1053

Andere talen

Filters